Astellas Pharma Inc
(OTC: ALPMY)
|
4:59 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $9.80 | Change: -0.01 | %Change: -0.15% | Volume: 51,511 |
Open: | $ 9.81 | Volume: | 51,511 | |
---|---|---|---|---|
High: | $ 9.83 | Yield(%) | 3.72 | |
Low: | $ 9.78 | P/E Ratio (ttm): | 149.71 | |
Dividend ($): | 0.20 | Market Cap ($): | 17.64B | |
EPS ($) | 0.06 | Shares Out: | 1.79B |
% Price Change (last 4 weeks): | -3.40 |
---|---|
% Price Change (last 13 weeks): | -9.56 |
% Price Change (last 26 weeks): | -17.20 |
% Price Change (last 52 weeks): | -33.74 |
% Price Change (year to date): | -17.72 |
Return on Equity (%): | 1.08 |
---|---|
Return on Assets (%): | 0.56 |
Return on Invested Capital (%): | 7.76 |
Gross Profit Margin (%): | 75.60 |
---|---|
Net Profit Margin (%): | 1.06 |
Operating Profit Margin (%): | 11.10 |
|
|
50-day Moving Average: | $9.77 |
---|---|
200-day Moving Average: | $11.30 |
Avg. Daily Vol. (last 50 days): | 343,387 |
Avg. Daily Vol. (last 200 days): | 308,053 |
52-wk high: | $15.90 |
52-wk low: | $9.15 |
Bid: | $n/a |
Ask: | $n/a |
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
|
Astellas Pharma Inc
2-5-1 Nihonbashi-Honcho Chuo-Ku Tokyo TY 103-8411 Phone: 81.3.3244.3000 Fax: n/a http://www.astellas.com |
Earnings (1year) ($): | 0.06 |
---|---|
Annual Dividend ($): | 0.37 |
Current P/E Ratio (ttm): | 149.71 |
Book Value ($): | 5.88 |
Cash Flow ($): | 0.67 |
Price/Earnings (x): | 149.71 |
---|---|
Price/Sales (x): | 1.74 |
Price/Book (x): | 1.83 |
Price/Cash Flow (x): | 15.41 |
Quick Ratio (x): | 0.74 |
---|---|
Current Ratio (x): | 0.93 |
LT Debt/Equity (x): | 32.49 |
Total Debt/Equity (x): | 63.02 |